Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer

Wolfgang Janni(Grace (United States)), Christos Papadimitriou(National and Kapodistrian University of Athens), Michelle DeSilvio(Newark Beth Israel Medical Center), Piotr Potemski(Copernicus Memorial Hospital), Elżbieta Starosławska(Lublin Oncology Center), Tomasz Sarosiek, Joanna Pikiel(Chemotherapy Foundation), Kim Mahood(Novartis (Switzerland)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Kathryn Jane Briggs(GlaxoSmithKline (United Kingdom)), Luca Marini, Étienne Brain(Institut Curie), Christoph Salat(Praxis für Hämatologie und Onkologie), Christian Caglevic
The Breast
September 16, 2015
10.1016/j.breast.2015.08.005
Cited by 11

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k